Metastatic cervical cancer presents new measures related to the association of biological
therapies with conventional treatment that varies according to the presence of biomarkers.
Based on a case report, we reviewed therapeutic modalities and updates on the use
of concomitant immunobiological and oncological treatments to combat invasive cervical
cancer. The use of pembrolizumab is a new option in patients with positive PD-L1 associated
with metastatic cervical cancer, having demonstrated a favorable toxicity profile
and improved survival. In this case report, we describe a 52-year-old woman diagnosed
with metastatic cervical cancer who underwent to chemotherapy (CT) with paclitaxel
and carboplatin, as well as immunotherapy with pembrolizumab for PD-L1 positive cervical
neoplasm and metastasectomy of hepatic lesions. The patient remains under outpatient
care with no signs of active disease.
Keywords
uterine cervical neoplasms - neoplasm metastasis - immunotherapy - neoplasm staging
- metastasectomy
Bibliographical Record
Luís Gustavo Ramos Raupp Pereira, Luísa Motter Comarú, Micael Guzzon, Eduarda Alberti
Lopes Silva, Júlhia Spuldaro Rabuske, Larissa Roberta Negrão, Raíssa dos Santos Copatti,
Paulo Roberto Reichert. Metastatic Cervix Uterine Cancer and Therapeutics Updates:
A Case Report and Literature Review. Brazilian Journal of Oncology 2025; 21: s00441800925.
DOI: 10.1055/s-0044-1800925
